AT:LCT Living Cell Technologies Ltd.

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. Living Cell Technologies Limited has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. The company was founded in 1987 and is based in Melbourne, Australia.This company has ADRs that trade in the U.S. as the symbol LVCLY.

0.01 AUD
As of 03/22/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/01/1900
Stock exchange:    Asx - All Markets
Exchange country:   Australia
Market cap:   5,141,800 AUD
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy